Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18260180 | 1.00 | AKT1 (0.34) | AKT1PPARGPPARAIDO1FFAR1 | |
| SCHEMBL18270056 | 0.94 | PPARG (0.32) | AKT1PPARGPPARA | |
| SCHEMBL18260157 | 0.94 | AKT1 (0.33) | AKT1PPARGPPARAIDO1FFAR1 | |
| SCHEMBL18260158 | 0.94 | AKT1 (0.33) | AKT1PPARGPPARAIDO1FFAR1 | |
| SCHEMBL18260161 | 0.92 | FFAR1 (0.37) | AKT1IDO1FFAR1AOC3 | |
| SCHEMBL18260162 | 0.92 | FFAR1 (0.37) | AKT1IDO1FFAR1AOC3 | |
| SCHEMBL18260185 | 0.91 | NPC1 (0.40) | AKT1PPARGPPARAIDO1FFAR1 | |
| SCHEMBL18260183 | 0.91 | NPC1 (0.40) | AKT1PPARGPPARAIDO1FFAR1 | |
| SCHEMBL18260225 | 0.86 | CYP1A2 (0.36) | PPARGFFAR1 | |
| SCHEMBL18260223 | 0.86 | CYP1A2 (0.36) | PPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | AOC3, OR51E2, AOC2 | AKT1 1244/4885PPARG 4463/4885PPARA 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.